Darzalex faspro, kyprolis, and dexamethasone is approved by FDA for multiple myeloma

Share This Post

March 2022: Daratumumab + hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) and carfilzomib (Kyprolis, Amgen, Inc.) plus dexamethasone have been approved by the Food and Drug Administration for adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.

PLEIADES (NCT03412565), a multi-cohort, open-label trial, was used to assess efficacy in a single-arm cohort. 66 individuals with relapsed or refractory multiple myeloma who had undergone at least one prior line of therapy were included in this study. Darzalex Faspro 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase) was given subcutaneously in combination with Kyprolis (20/70 mg/m2 once weekly regimen) and dexamethasone to the patients.

The overall response rate was the primary efficacy outcome measure (ORR). The ORR for this study was 84.8 percent (95 percent CI: 73.9 percent , 92.5 percent ). The median length of response had not been attained at a median follow-up of 9.2 months, but an estimated 85.2 percent (95 percent CI: 72.5, 92.3) maintained response for at least 6 months and 82.5 percent (95 percent CI: 68.9, 90.6) maintained response for at least 9 months.

Upper respiratory tract infections, fatigue, insomnia, hypertension, diarrhoea, cough, dyspnea, headache, pyrexia, nausea, and edoema peripheral were the most prevalent side events (20%) in patients treated with Darzalex Faspro, Kyprolis, and dexamethasone.

Darzalex Faspro is administered subcutaneously at a dose of 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase) once weekly from Weeks 1 to 8, once every 2 weeks from Weeks 9 to 24, and once every 4 weeks starting Week 25 until disease progression or intolerable toxicity.

The recommended dosage regimens of Kyprolis when administered in combination with Darzalex Faspro are the following:

  • Once weekly 20/70 mg/m2 regimen: Kyprolis 20 mg/m2 administered by IV infusion over 30 minutes on Cycle 1 Day 1 and if a dose of 20 mg/m2 is tolerated, 70 mg/m2 as a 30-minute IV infusion on Cycle 1, Day 8 and Day 15, and then Day 1, 8, and 15 of each 28-day cycle.
  • Twice weekly 20/56 mg/m2 regimen: Kyprolis 20 mg/m2 administered by IV infusion over 30 minutes on Cycle 1 Day 1 and Day 2 and, if a dose of 20 mg/m2 is tolerated, 56 mg/m2 administered by IV infusion over 30 minutes on Cycle 1, Day 8, 9, 15, and 16, and then on Day 1, 2, 8, 9, 15, 16 of each 28-day cycle.

CAR T-Cell therapy is among the latest breakthrough therapy in the treatment of multiple myeloma. Know more about CAR T-Cell therapy here.

Apply for CAR T-Cell therapy


Apply Now

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy